Anavex Life Sciences Corp (AVXL)

[RedShoulder]

AVXL compared to SAVA. Simufilam is downstream from the Anavex's upstream targets of the S1 receptors and several muscarinic receptors. A2-73 Blarcamesine restores the S1-R to homeostasis with many benefits, including properly folding the downstream proteins where Simufilam is attempting to do the same. .

Once Anavex's drug A2-73 Blarcamesine is FDA, TGA, EMA, GB is approved, Simufilam which is downstream, will no longer be needed and redundant.

Why would any investor with this knowledge would invest in SAVA ?.

SAVA's one drug Simufilam only targets Alzheimer.

Whereas AVXL's multiple drugs A2-73, A3-71, A1-41, A-1066 treats multiple CNS diseases, such as:
Alzheimer,
Parkinson dementia,
Parkinson,
Rett, Fragile X,
Infantile Spasms,
Angelman Syndrome,
an Undisclosed Rare Disease,
Frontotemporal Dementia,
Neurodegenerative Diseases,
Depression, Stroke,
Visceral Pain,
Acute & Neuropathic Pain,
and many other future CNS targets.

If a SAVA shareholder sold shares at today's share prices, they could buy over 2 1/2 shares of AVXL for every SAVA share sold.

https://www.anavex.com/therapeutic-candidates